All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Amgen’s monoclonal antibody densoumab is edging closer towards approval in the European Union (EU) for the treatment of Multiple Myeloma (MM) patients with Skeletal Related Events (SREs). On 23 February 2018, the Committee for Medicinal Products for Human Use (CHMP) recommended an expansion of the current indication for denosumab, having reviewed recent phase III trial data to assess denosumab in comparison with the currently used drug zoledronic acid (ZA) – see previous MM Hub article.
The study enrolled 1718 Newly Diagnosed (ND) MM patients and indicated a superior progression-free survival (PFS) with denosumab (46.1 months) compared to ZA (35.4 months). Importantly, denosumab led to less renal toxicity (10% vs 17%) in comparison to ZA, which can be nephrotoxic if taken long-term. This, therefore, offers a safer long-term option to MM patients with SREs at risk of developing renal complications, or those already presenting with severe renal damage.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox